| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 21.77B | 18.52B |
| Cost of Revenue | 10.94B | 9.21B |
| Gross Profit | 10.83B | 9.31B |
| Operating Expenses | 3.29B | 6.43B |
| Research and Development | 199.32M | 158.89M |
| Selling, General & Administrative Expenses | 3.06B | 2.52B |
| Selling & Marketing Expenses | 1.27B | 1.03B |
| General & Administrative Expenses | 176.97M | 162.62M |
| Other Expenses | 0 | 593.13M |
| Operating Income | 7.79B | 2.88B |
| Total Other Income/Expenses Net | -3.56B | -3.06B |
| Income Before Tax | 4.24B | 3.38B |
| Income Tax | 1.09B | 723.32M |
| Net Income | 3.14B | 2.66B |
| Basic EPS | 6.92 | 6.41 |
| EPS Diluted | 6.92 | 6.41 |
| Basic Average Shares | 453.32M | 415.4M |
| Diluted Average Shares | 453.16M | 415.4M |
| EBITDA | 5.09B | 3.99B |
Marksans Pharma Limited
MARKSANS.NS
NSE
205.58INR11.43 (6.52%)
MARKSANS.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 10.91B | 5.09B |
| Net Income | 3.14B | 2.66B |
| Stock Repurchases | 0 | -451.66M |
| Dividend Paid | -226.58M | -101.71M |
| Retained Earnings | 10.69B | 10.91B |
| Other Distributions | -450.69M | 5.27B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 6.93B | 3.87B |
| Annual Depreciation | 742.7M | 518.53M |
| Capital Expenditure | -2.09B | -536.31M |
| Net PPE | 8.28B | 3.89B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 10.1M | 84.64M |
| Goodwill (Previous Year) | 384.89M | 300.25M |
| Goodwill | 394.99M | 384.89M |